Navigation Links
Rakesh Bamzai Joins Mylan as President, India Commercial and Emerging Markets
Date:1/2/2014

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Rakesh Bamzai has joined the company and has been appointed president, India Commercial and Emerging Markets.

Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, where he played a key role in building the company's global biopharmaceutical business. He had overall responsibility for active pharmaceutical ingredients (API) and branded formulations and managed a team of more than 2,000 people across functional areas and geographies. Through the years, he also spearheaded many strategic partnerships that enabled the organization to gain wider global access and greater market penetration for its biopharmaceuticals business. Bamzai also led Biocon's foray into branded formulations and built many successful brands across therapies in India and Gulf Cooperation Council states.

Mylan President Rajiv Malik commented, "We were extremely pleased when Rakesh asked to join our company. Many of us at Mylan have had a firsthand opportunity to work with Rakesh over the course of our strategic partnership with Biocon and have observed his strong business and marketing acumen, his strategic insight and outstanding leadership skills. In this new role overseeing all of Mylan's commercial operations in India and emerging markets, we believe that Rakesh will add significant value to Mylan."

Bamzai said, "I have had the privilege of collaborating with Mylan during my time at Biocon, and I am excited about the significant opportunities I see for the company in India and other emerging markets. I believe Mylan's commitment to quality and to setting new standards for innovation, reliability and service for patients and physicians in India will further distinguish Mylan from its peers. I look forward to supporting Mylan's continued expansion and differentiation in these exciting growth markets."

Bamzai graduated from the University of Mumbai (Department of Chemical Technology).

This press release includes statements that constitute "forward-looking statements," including with regard to the company's future growth and performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; the ability to attract and retain key personnel; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Molecular Profiles Joins Leading Consortium To Drive Paediatric Formulation Development
2. The Regional Food Bank of Oklahoma Joins Forces with Watertree Health to Build Stronger, Healthier Communities
3. Francesco Granata, M.D. Joins Board of Prismic Pharmaceuticals
4. Guri Stark Joins CorTechs Labs as CEO
5. Eisai Joins Groundbreaking Tuberculosis Drug Accelerator Partnership to Discover New Tuberculosis Drugs
6. BD Joins National Patient Safety Foundation Corporate Council, Furthers Commitment to Safety
7. Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
8. Helping New Yorkers Prevent Heart Attacks: Itamar Medical Joins The Fight With New Campaign
9. Bay Alarm Medical Joins The Fight To End Hunger
10. Chris Newmarker joins MPMN and Qmed
11. State Senator Mae Beavers Joins Local Leaders, Retailers, Pharmacists To Launch Anti-Smurfing Public Awareness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017   Pulmatrix, Inc . (NASDAQ: PULM), a clinical ... pulmonary diseases, today announced that it has added two experts ... asthma to its Scientific Advisory Board . ... B. Moss , MD, former chief of the Pediatric Pulmonary ... Center at Stanford University, and David ...
(Date:3/27/2017)... March 27, 2017  iCAD (Nasdaq: ICAD), an ... and radiation therapy for the early identification and ... Detection received Premarket Approval (PMA) from the U.S. ... is a first-of-its-kind, concurrent-read computer aided detection solution ... latest innovation available on the PowerLook® Breast Health ...
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... clear braces. People who want straight teeth without the extensive time commitment and ... Clearwater, FL, without acquiring a referral. A custom-designed series of virtually invisible aligners ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the ... popHealth Community in 2014. It is the culmination of collaborative efforts by ... Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first ... for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to ... such as ANSI, ISO and proven test methods used in the field of ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research study, ... having the skills needed to execute that strategy, and the actual success of ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer Society ... is more than 95%. Once the cancer spreads to other organs, bones, or lymph ... out how to avoid this latter group, tune in to Lifestyle Magazine ...
Breaking Medicine News(10 mins):